. Characterisation of the rabbit monoclonal Rab12-pS106 (MJF-25-9-1) antibody. (A) HEK293 cells were co-transfected with plasmids encoding the LRRK2[Y1699C] pathogenic mutation and the indicated Rab protein that all possessed an Nterminal HA tag. 36 hours post transfection, cells were treated ± 150 nM MLi-2 inhibitor for 90 min prior to cell lysis. 0.5 µg of whole cell extract was subjected to quantitative immunoblot analysis with the indicated antibodies (all at 1 µg/ml primary antibody concentration), and the membranes developed using the Odyssey CLx scan Western Blot imaging system. (B) The indicated wild type and Rab12 knock-out A549 cells were treated ± 100 nM MLi-2 for 90 min prior to cell lysis. Generation of the Rab12 knock-out cells is described in the materials and methods. 30 µg of whole cell extract was subjected to quantitative immunoblot analysis with the indicated antibodies (all at 1 µg/ml primary antibody concentration). The membranes developed using the Odyssey CLx scan Western Blot imaging system. A duplicate Rab12-pS106 immunoblot analysis was developed using enhanced chemiluminescence (ECL) for comparison. Purified monocytes were stained with the monocyte specific marker CD14 employing antihuman CD14 V500 antibody while purified neutrophils were stained with the granulocyte specific marker CD66b using anti-human CD66b FITC antibody. Cells were also stained with the cell viability dye DAPI. Cells were analysed by flow cytometry revealing that isolated monocytes had a viability >99% and a purity 87-90%, while isolated neutrophils had a viability >99% and a purity 94-98%. PBMC were stained with the B cell marker CD19 APC, the T cell marker CD3 PE, the monocyte marker CD14 V500, the granulocyte marker CD66b FITC and DAPI. * corresponds to the monocyte and granulocyte parent gate. The proportion of each cell type within the isolated PBMC is provided. The data shown is for Donor A. A summary of the viability and purity data for all three donors is provided in Figure 6A . 
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